Kidney drug tolvaptan monitored in 1,800 patients: real-world results show promise
NCT ID NCT02847624
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 14 times
Summary
This study followed 1,802 people in Japan with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan. The goal was to see how safe and effective the drug is in everyday medical practice. Researchers measured kidney volume changes and checked for liver side effects. The study helps doctors understand how well tolvaptan works outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.